A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market
Hyperhidrosis is a chronic disorder of excessive sweating beyond thermoregulatory needs and environmental conditions. It commonly arises in childhood and adolescence, and can affect patients for many years. Most cases of hyperhidrosis involve areas of high eccrine (sweat gland) density, particularly in the armpits, palms and soles, and less often in the facial area. According to the International Hyperhidrosis Society (IHS), the global prevalent population of hyperhidrosis is 367 million. The US has the most hyperhidrosis cases among the major developed countries covered in this report. Hyperhidrosis occurs in men and women equally, and can present at any age.
Primary axillary hyperhidrosis therapeutics market for the seven major markets is expected to grow to $680.7m by 2023, at a compound annual growth rate (CAGR) of 3.3%. This expected growth is due to increasing awareness of primary axillary hyperhidrosis as a treatable medical condition across the major developed markets, thus resulting in an increased diagnosis rate, and therefore a larger treatment-receiving population.
United States has the most hyperhidrosis cases amongst the major developed countries covered in this report. The reported prevalence rate for hyperhidrosis in the US is approximately 4.8%. Of these sufferers, 65% have axillary hyperhidrosis. In 2013, the reported prevalence rate for primary axillary hyperhidrosis in Japan was 5.75%, meaning nearly 2.23 million people suffered from severe symptoms of primary axillary hyperhidrosis. In 2016 the reported prevalence rate for primary focal hyperhidrosis in Germany was 4.6%. The reported prevalence rate for hyperhidrosis in the UK in 2005 stood at 1.62%. There are more than 1.2 million hyperhidrosis prevalent cases in Spain.
Allergan’s Botox is the only approved product to treat primary axillary hyperhidrosis. Botox’s major competitors are other botulinum toxin products such as Dysport and Xeomin, which are currently used off-label to treat the condition. Botox’s revenue in this indication is expected to decline over the period due to competition from existing off-label products, and an increasing preference for medical devices that can provide permanent treatment for the disease.
The report “A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market” provides an in-depth assessment of the current trends in the global hyperhidrosis market, with a particular focus on primary axillary hyperhidrosis. This report also assesses the commercial landscape through multilevel analytics that include data split by stage of development, molecular target, molecule type and route of administration.
Primary axillary hyperhidrosis in the major developed markets will show a slight increase in growth rate during the forecast period
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook